News

U.S. Food and Drug Administration Approves First CAR T Cell Therapy for Mantle Cell Lymphoma: Brexucabtagene Autoleucel (TECARTUS)

Brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company) has been approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). This is the first chimeric antigen receptor (CAR) T cell therapy approved for MCL.

Steven Eichberg Elected Chair of LRF Board of Directors

Eichberg, a Board member since 2019, assumed his new duties from outgoing Chair Michael Werner, whose four-year term concluded on June 30.

LRF Scientific Advisory Board Gains New International Leaders in Lymphoma

The Lymphoma Research Foundation (LRF) welcomes three new members to their elite Scientific Advisory Board (SAB). The new members represent distinct specialties that will contribute to the international impact of the Lymphoma Research Foundation.

Lymphoma Research Foundation Hosts Inaugural Swirl: America, An At Home Tasting Virtual Fundraiser

LRF Spokesperson and acclaimed journalist Lisa Guerrero kicks off nationwide cheeseboard challenge to drive lymphoma awareness.

U.S. Food and Drug Administration Approves Selinexor (XPOVIO) for Diffuse Large B-cell Lymphoma

Selinexor (XPOVIO, Karyopharm Therapeutics, Inc.) is a single-agent oral tablet approved for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma (FL), after at least 2 lines of systemic therapy.

U.S. Food and Drug Administration Approves Tazemetostat (TAZVERIK) and EZH2 Mutation Test for Follicular Lymphoma

Tazemetostat (TAZVERIK), an EZH2 inhibitor, and the EZH2 Mutation Test were granted approval for adult patients with relapsed or refractory follicular lymphoma (FL).

Meet the 2020 Lymphoma Clinical Mentoring Program Scholars

The new class of LRF Scholars is pursuing research projects covering a diverse range of lymphoma subtypes with a goal to improve patient outcomes.

Bridging the Gap in Adolescent and Young Adult Lymphoma

Dr. Kara Kelly is helping to build the bridge between AYA, and pediatric and adult oncology fields to bring attention to this underserved population and improve patient care.

An Emerging Cancer: Survivors Advocate for Women’s Health and Awareness

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is impacting women globally—leaving many questions for both patients and providers.

In the Business of Giving Back

Being a socially responsible company helps businesses “do good” while building credibility among its customers and employees.

Subscribe to Our Emails. Get lymphoma and CLL resources and updates.